PT-141 10mg/vial – US Stock

PT-141 10mg/vial – US Stock
PT-141 10mg/vial from Hilma Biocare contains PT-141, also known as Bremelanotide. The product is supplied as a lyophilized injection/powder formulation with 10 mg of active compound per vial and is listed as US Stock.
Product Overview
PT-141 is described in the supplied product information as the laboratory code for Bremelanotide, a peptide and metabolite of Melanotan-2. The source describes its activity in relation to melanocortin receptors, including MC3R and MC4R, and discusses research and clinical trials involving sexual function.
The supplied specifications identify PT-141 (Bremelanotide) as the active compound, with a listed active half-life of 120–160 minutes.
Key Product Characteristics

Active Ingredient: PT-141 (Bremelanotide)
Strength: 10 mg/vial
Form: Injection/powder
Product Type: Peptide hormone
Pack Size: 1 vial
Active Half-Life: 120–160 minutes
Manufacturer/Brand: Hilma Biocare
US Availability: US Stock
Water Retention: Listed as No
Aromatization: Listed as No

Product Specifications

Specification
Details

Brand
Hilma Biocare

Active Ingredient
PT-141 (Bremelanotide)

Strength
10 mg/vial

Form
Injection/powder

Product Type
Peptide hormone

Pack Size
1 vial

Active Half-Life
120–160 minutes

Water Retention
No, according to supplied specifications

Aromatization
No, according to supplied specifications

Product Characteristics
The supplied description characterizes PT-141 as a peptide that acts on melanocortin receptors and describes its activity in both the central nervous system and pathways associated with blood flow.
The source also discusses clinical research concerning sexual disorders and describes effects involving libido. It further states that PT-141 can stimulate melanin production by melanocytes. These statements are based on the supplied product material and should not be interpreted as personalized medical advice or as a guarantee of clinical outcomes.
About Hilma Biocare USA
PT-141 10mg/vial is part of the Hilma Biocare product range. It is supplied in a 1-vial format containing 10 mg of PT-141 (Bremelanotide) and is listed as US Stock.
Important Information
PT-141/Bremelanotide is a medically relevant peptide compound. The supplied source contains administration, dosing, treatment-duration, and contraindication information. Actionable dosing schedules and self-administration instructions are not reproduced here.
The supplied information identifies hypertension, cardiovascular disease, liver disease, kidney disease, cancer, pregnancy, lactation, and hypersensitivity as contraindication considerations. Anyone considering a medically relevant peptide product should consult an appropriately qualified healthcare professional regarding suitability, potential risks, contraindications, and interactions.